Neurocrine Biosciences
NBIX
587 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2025 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 190 increasing their positions, 251 reducing their positions, and 82 closing their positions.
44% more call options, than puts
Call options by funds: $92.7M | Put options by funds: $64.6M
3.45% more ownership
Funds ownership: 93.41% → 96.86% (+3.4%)
10% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 82
2% less funds holding
Funds holding: 600 → 587 (-13)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
17% less capital invested
Capital invested by funds: $12.9B → $10.7B (-$2.23B)
24% less repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 251
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$319M |
| 2 |
JP Morgan Chase
New York
|
+$165M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$85.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$81.1M |
| 5 |
DM
Deerfield Management
New York
|
+$79.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$209M |
| 2 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$127M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$104M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$64.5M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$55.9M |
NBIX Hedge Fund Activity: Q1 2025 in Review
587 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2025, worth a combined $10.7B — down 17% from $12.9B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of NBIX and 74 opened new positions — a net loss of 8 holders — while 251 trimmed existing stakes and 190 added.
The largest buyer was Dodge & Cox, adding an estimated $319M. The largest seller was Citadel Advisors, cutting an estimated $209M.
- 587 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2025, down from 600 in Q4 2024.
- Funds reported $10.7B of Neurocrine Biosciences stock for Q1 2025, down 17% quarter-over-quarter.
- 74 funds opened new Neurocrine Biosciences positions in Q1 2025 and 82 closed out, a net change of -8 holders.
- The largest Neurocrine Biosciences buyer in Q1 2025 was Dodge & Cox, an estimated $319M added.
- The largest Neurocrine Biosciences seller in Q1 2025 was Citadel Advisors, an estimated $209M sold.
Based on aggregated 13F filings for Q1 2025.